Cargando…
Capecitabine-Associated Terminal Ileitis
Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243901/ https://www.ncbi.nlm.nih.gov/pubmed/30483093 http://dx.doi.org/10.1159/000492781 |
_version_ | 1783372004778311680 |
---|---|
author | van Hellemond, Irene E.G. Thijs, Annemarie M. Creemers, Geert-Jan |
author_facet | van Hellemond, Irene E.G. Thijs, Annemarie M. Creemers, Geert-Jan |
author_sort | van Hellemond, Irene E.G. |
collection | PubMed |
description | Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecitabine-induced terminal ileitis is likely to be underreported. It should be considered more often as a cause of severe and atypical complaints of diarrhea during treatment with capecitabine or other 5-fluorouracil agents. |
format | Online Article Text |
id | pubmed-6243901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-62439012018-11-27 Capecitabine-Associated Terminal Ileitis van Hellemond, Irene E.G. Thijs, Annemarie M. Creemers, Geert-Jan Case Rep Oncol Case Report Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecitabine-induced terminal ileitis is likely to be underreported. It should be considered more often as a cause of severe and atypical complaints of diarrhea during treatment with capecitabine or other 5-fluorouracil agents. S. Karger AG 2018-10-22 /pmc/articles/PMC6243901/ /pubmed/30483093 http://dx.doi.org/10.1159/000492781 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report van Hellemond, Irene E.G. Thijs, Annemarie M. Creemers, Geert-Jan Capecitabine-Associated Terminal Ileitis |
title | Capecitabine-Associated Terminal Ileitis |
title_full | Capecitabine-Associated Terminal Ileitis |
title_fullStr | Capecitabine-Associated Terminal Ileitis |
title_full_unstemmed | Capecitabine-Associated Terminal Ileitis |
title_short | Capecitabine-Associated Terminal Ileitis |
title_sort | capecitabine-associated terminal ileitis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243901/ https://www.ncbi.nlm.nih.gov/pubmed/30483093 http://dx.doi.org/10.1159/000492781 |
work_keys_str_mv | AT vanhellemondireneeg capecitabineassociatedterminalileitis AT thijsannemariem capecitabineassociatedterminalileitis AT creemersgeertjan capecitabineassociatedterminalileitis |